Trial Profile
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2022
Price :
$35
*
At a glance
- Drugs Astegolimab (Primary)
- Indications Acute asthma; Asthma
- Focus Therapeutic Use
- Acronyms ZENYATTA
- Sponsors Genentech; Roche
- 29 Dec 2021 Results of population pharmacokinetics and exposure-response relationships of astegolimab in patients with severe asthmapublished in the Journal of Clinical Pharmacology
- 16 Apr 2021 Primary endpoint (Rate of Asthma Exacerbations) has been met, as per results published in the Journal of Allergy and Clinical Immunology
- 16 Apr 2021 Results published in the Journal of Allergy and Clinical Immunology